The record
Written from the 1 report below. Nothing here is unsourced.
- The ICMR has transferred rights to three homegrown medical technologies to Emcure Pharmaceuticals and Biological E under its Medical Innovations Patent Mitra programme to turn publicly funded research into affordable products.
- Emcure gets SHetA2, a drug candidate for treating cervical pre-cancerous lesions (CIN) that targets HPV-damaged cells while sparing healthy ones.
- Biological E gets two next-generation vaccine candidates from ICMR's Kolkata lab, one against typhoid and one against typhoid, paratyphoid and Shigella.
- ICMR says the moves could strengthen cervical cancer prevention and infectious disease control while reducing reliance on imported medical technologies.
What to watch next
- Clinical trial results for SHetA2's safety, dosing and efficacy before it can enter routine practice
- Progress of the two Biological E vaccines towards testing and regulatory approvals
- Whether future transfers under the Patent Mitra programme cover other HPV-related conditions noted by experts
Coverage1
1 report
English national1
All filed from India
Named India · United States · All India Institute of Medical Sciences · Bimal Kumar Das · Biological E · Department of Health Research · Emcure Pharmaceuticals · Hitender Gautam · Indian Council of Medical Research · Medical Innovations Patent Mitra · National Institute for Research in Bacterial Infections · National Institute of Cancer Prevention and Research · Rajiv Bahl · Sandeep Nayak
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.